BIA announces new appointments to the BIA Board at 2018 AGM

Following the BIA AGM last week, the Association has announced the new members who have been elected to its Board of Directors. The AGM took place on Thursday 18th October at the QEII Centre as part of the BIA’s annual UK Bioscience Forum and the new board members were voted for by the BIA’s membership in the weeks leading up to the meeting.

There were four corporate places and one ‘other’ member place to fill at the election and the new Board members who will join the Board from January 1st 2019 for a three year term are:

 

Corporate Board Members:

  • Lisa Anson of Redx Pharma

  • Charlotte Casebourne of Theolytics

  • Oliver Hardick of Puridify

  • Andrew Hotchkiss of Immunocore

Other Board Member:

  • Clare Terlouw of Syncona

 

BIA CEO Steve Bates said: “These new appointments, emphasise the diversity of the membership we represent. They build on the current strength of the BIA Board and broaden our expertise as the Association continues to take on the challenges presented by Brexit to ensure that our members can grow and be successful.”

 

Chair of the BIA Board, Dr Jane Osbourn said: “We had an outstanding and comprehensive range of candidates stand for election this year and I would encourage all of those who were not successful this time around to look at standing next year. The BIA Board does an excellent job of representing the membership and leading the Association’s work and I look forward to working with the new Directors over the coming year.”

 

For more information on the BIA Board – go to the about us section on the BIA website https://www.bioindustry.org/about-us.html

 

Ends

 

Notes to editors

Contact:

Ed Sexton, BIA Communications and Media Relations Manager – esexton@bioindustry.org 0207 630 2196

 

About the UK BioIndustry Association (BIA)

Established over 25 years ago at the infancy of biotechnology, the BioIndustry Association (BIA) is the trade association for innovative enterprises involved in UK bioscience. Members include emerging and more established bioscience companies; pharmaceutical companies; academic, research and philanthropic organisations; and service providers to the bioscience sector. The BIA represents the interests of its members to a broad section of stakeholders, from government and regulators to patient groups and the media. Our goal is to secure the UK's position as a global hub and as the best location for innovative research and commercialisation, enabling our world-leading research base to deliver healthcare solutions that can truly make a difference to people's lives.

 

For further information, please go to www.bioindustry.org and twitter.com/BIA_UK

More within